{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:58:04Z","timestamp":1791334684965,"version":"4.3.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.euf.2025.02.006","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T15:33:01Z","timestamp":1740670381000},"page":"223-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antimuscarinics or \u03b23 Adrenoreceptor Agonists: Which Should Be the First Step?"],"prefix":"10.1016","volume":"11","author":[{"given":"Maria Lucia","family":"Gallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"Przydacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Ph\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.02.006_b0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.02.006_b0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/nau.23893","article-title":"Which anticholinergic is best for people with overactive bladders? A network meta-analysis","volume":"38","author":"Herbison","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2025.02.006_b0015","unstructured":"Harding CK, Lapitan MC, Arlandis S, et al. EAU guidelines on management of non-neurogenic female lower urinary tract symptoms. Arnhem, The Netherlands: European Association of Urology; 2024."},{"key":"10.1016\/j.euf.2025.02.006_b0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.euf.2025.02.006_b0025","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sc.2013.19","article-title":"Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics","volume":"51","author":"Madersbacher","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1016\/j.euf.2025.02.006_b0030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/AOG.0000000000000468","article-title":"Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence","volume":"124","author":"Kalder","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.euf.2025.02.006_b0035","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.02.006_b0040","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/iju.13498","article-title":"Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms\/overactive bladder: comparison with placebo and tolterodine","volume":"25","author":"Sebastianelli","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2025.02.006_b0045","unstructured":"Blok B, Castro-Diaz D, Del Popolo G, et al. EAU guidelines on neurourology. Arnhem, The Netherlands: European Association of Urology; 2024."},{"key":"10.1016\/j.euf.2025.02.006_b0050","doi-asserted-by":"crossref","unstructured":"Kennelly M, Wielage R, Shortino D, Thomas E, Mudd PN Jr. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context 2022;11:2022-4-2.","DOI":"10.7573\/dic.2022-4-2"},{"key":"10.1016\/j.euf.2025.02.006_b0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/luts.12253","article-title":"Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice","volume":"11","author":"Shin","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2025.02.006_b0060","unstructured":"Cornu JN, Gacci M, Hashim H, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS). Arnhem, The Netherlands: European Association of Urology; 2024."}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:14:45Z","timestamp":1760073285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2405456925000434"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.02.006","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimuscarinics or \u03b23 Adrenoreceptor Agonists: Which Should Be the First Step?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}